|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2011-6-20
|
|
pubmed:abstractText |
To study the incidence and prognostic impact of mutations in Additional sex comb-like 1 (ASXL1) in a large cohort of patients with myelodysplastic syndrome (MDS). PATIENTS, MATERIALS, AND METHODS: Overall, 193 patients with MDS and 65 healthy volunteers were examined for ASXL1 mutations by direct sequencing and for expression levels of ASXL1. The prognostic impact of ASXL1 mutation and expression levels was evaluated in the context of other clinical and molecular prognostic markers.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:BugGesineG,
pubmed-author:ChaturvediAnuharA,
pubmed-author:DammFrederikF,
pubmed-author:FriesenInnaI,
pubmed-author:GöhringGudrunG,
pubmed-author:GanserArnoldA,
pubmed-author:HeuserMichaelM,
pubmed-author:HofmannWolf-KarstenWK,
pubmed-author:KrauterJürgenJ,
pubmed-author:OttmannOliverO,
pubmed-author:SchlegelbergerBrigitteB,
pubmed-author:SchumannChristianeC,
pubmed-author:SharmaAmitA,
pubmed-author:TholFelicitasF,
pubmed-author:WagnerKatharinaK,
pubmed-author:WeissingerEva MEM,
pubmed-author:WichmannMartinM,
pubmed-author:YunHaiyangH
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2499-506
|
|
pubmed:dateRevised |
2011-9-30
|
|
pubmed:meshHeading |
pubmed-meshheading:21576631-Adult,
pubmed-meshheading:21576631-Aged,
pubmed-meshheading:21576631-Aged, 80 and over,
pubmed-meshheading:21576631-Antilymphocyte Serum,
pubmed-meshheading:21576631-Biological Markers,
pubmed-meshheading:21576631-Clinical Trials as Topic,
pubmed-meshheading:21576631-DNA Methylation,
pubmed-meshheading:21576631-DNA Mutational Analysis,
pubmed-meshheading:21576631-Disease Progression,
pubmed-meshheading:21576631-Exons,
pubmed-meshheading:21576631-Female,
pubmed-meshheading:21576631-Follow-Up Studies,
pubmed-meshheading:21576631-Frameshift Mutation,
pubmed-meshheading:21576631-Gene Expression Profiling,
pubmed-meshheading:21576631-Genes, MHC Class II,
pubmed-meshheading:21576631-Humans,
pubmed-meshheading:21576631-Kaplan-Meier Estimate,
pubmed-meshheading:21576631-Leukemia, Myeloid, Acute,
pubmed-meshheading:21576631-Male,
pubmed-meshheading:21576631-Middle Aged,
pubmed-meshheading:21576631-Multicenter Studies as Topic,
pubmed-meshheading:21576631-Myelodysplastic Syndromes,
pubmed-meshheading:21576631-Point Mutation,
pubmed-meshheading:21576631-Prognosis,
pubmed-meshheading:21576631-Proportional Hazards Models,
pubmed-meshheading:21576631-RNA, Messenger,
pubmed-meshheading:21576631-Repressor Proteins,
pubmed-meshheading:21576631-Risk
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
|
|
pubmed:affiliation |
Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg Str. 1, 30625 Hannover, Germany. thol.felicitas@mh-hannover.de
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
